Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.
코호트
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
609 patients with cN+ breast cancer treated with NAC followed by surgery across 7 institutions.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] A combination of ypT, ycN, and HR/HER2 status was strongly associated with ypN0 in patients with cN+ breast cancer. These findings represent a bridging study supporting risk stratification and the design of future trials evaluating axillary surgery omission.
OpenAlex 토픽 ·
Breast Cancer Treatment Studies
HER2/EGFR in Cancer Research
Esophageal Cancer Research and Treatment
[INTRODUCTION] Clinical trials are evaluating axillary surgery de-escalation after neoadjuvant chemotherapy (NAC) in patients achieving a breast pathological complete response (pCR).
APA
H. SHIGEMATSU, Shinsuke Sasada, et al. (2026). Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.. Clinical breast cancer, 26(5), 75-82. https://doi.org/10.1016/j.clbc.2026.03.016
MLA
H. SHIGEMATSU, et al.. "Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.." Clinical breast cancer, vol. 26, no. 5, 2026, pp. 75-82.
PMID
41996729 ↗
Abstract 한글 요약
[INTRODUCTION] Clinical trials are evaluating axillary surgery de-escalation after neoadjuvant chemotherapy (NAC) in patients achieving a breast pathological complete response (pCR). We investigated ypN0 rates according to ypT stage in patients with cN+ breast cancer treated with NAC.
[MATERIALS AND METHODS] We retrospectively analyzed 609 patients with cN+ breast cancer treated with NAC followed by surgery across 7 institutions. ypT was classified as ypT0, ypTis, or non-ypT0/Tis. Tumors were classified into biological subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Logistic regression analysis was performed to identify factors associated with ypN0. The frequency of ypN0 was evaluated according to ypT stage, ycN, and tumor subtype.
[RESULTS] Overall, ypN0 was achieved in 54.0% of patients. After NAC, 71.9% of patients were classified as ycN0, and ypT0, ypTis, and non-ypT0/Tis were observed in 21.5%, 10.3%, and 68.1% of patients, respectively. In multivariable analysis, ypT stage (ypT0: odds ratio [OR] 13.2; ypTis: OR 4.8), ycN0 (OR 4.5), HER2 positivity (OR 3.1), and HR negativity (OR 2.1) were independent predictors of ypN0. Among patients with ypT0 and ycN0, ypN0 rates exceeded 90%, reaching 97.1% in the HR-positive/HER2-positive subtype, 97.6% in the HR-negative/HER2-positive subtype, and 96.7% in the HR-negative/HER2-negative subtype.
[CONCLUSION] A combination of ypT, ycN, and HR/HER2 status was strongly associated with ypN0 in patients with cN+ breast cancer. These findings represent a bridging study supporting risk stratification and the design of future trials evaluating axillary surgery omission.
[MATERIALS AND METHODS] We retrospectively analyzed 609 patients with cN+ breast cancer treated with NAC followed by surgery across 7 institutions. ypT was classified as ypT0, ypTis, or non-ypT0/Tis. Tumors were classified into biological subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Logistic regression analysis was performed to identify factors associated with ypN0. The frequency of ypN0 was evaluated according to ypT stage, ycN, and tumor subtype.
[RESULTS] Overall, ypN0 was achieved in 54.0% of patients. After NAC, 71.9% of patients were classified as ycN0, and ypT0, ypTis, and non-ypT0/Tis were observed in 21.5%, 10.3%, and 68.1% of patients, respectively. In multivariable analysis, ypT stage (ypT0: odds ratio [OR] 13.2; ypTis: OR 4.8), ycN0 (OR 4.5), HER2 positivity (OR 3.1), and HR negativity (OR 2.1) were independent predictors of ypN0. Among patients with ypT0 and ycN0, ypN0 rates exceeded 90%, reaching 97.1% in the HR-positive/HER2-positive subtype, 97.6% in the HR-negative/HER2-positive subtype, and 96.7% in the HR-negative/HER2-negative subtype.
[CONCLUSION] A combination of ypT, ycN, and HR/HER2 status was strongly associated with ypN0 in patients with cN+ breast cancer. These findings represent a bridging study supporting risk stratification and the design of future trials evaluating axillary surgery omission.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.
- Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
- [Update on the regression grading of non-small cell lung cancer].
- Combined Impact of Neoadjuvant Therapy and Preoperative Cachexia in Patients Undergoing Pancreatoduodenectomy: Is There a "Double Jeopardy"? A National Cohort Study Investigating the Association with Short- and Long-Term Outcomes.
- Artificial Intelligence in Triple-Negative Breast Cancer: Applications in Diagnosis, Treatment Response, and Prognosis.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.